research use only
Cat.No.S8506
| Related Targets | PD-1/PD-L1 STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other CXCR Inhibitors | AZD5069 SB 225002 Reparixin (Repertaxin) WZ811 LIT-927 AMG 487 SX-682 LY2510924 UNBS5162 Danirixin (GSK1325756) |
|
In vitro |
DMSO
: 79 mg/mL
(198.78 mM)
Ethanol : 79 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 397.42 | Formula | C21H23N3O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 473727-83-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | MK-7123, PS-291822 | Smiles | CCC(C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C | ||
| Targets/IC50/Ki |
CXCR2
(Cell-free assay) 2.6 nM
CXCR1
(Cell-free assay) 36 nM
|
|---|---|
| In vitro |
Navarixin (SCH-527123, MK-7123, PS-291822) is a potent, orally bioavailable CXCR2/CXCR1 antagonist with IC50 values of 2.6 nM and 36 nM, respectively. |
| In vivo |
SCH52712, a novel, orally active CXCR1/2 receptor antagonist, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01068145 | Terminated | Chronic Obstructive Pulmonary Disease |
Merck Sharp & Dohme LLC |
February 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.